- Galectin Therapeutics (GALT +3.2%) trades higher after the company says GR-MD-02 and GM-CT-01 demonstrated a "positive therapeutic effect" in NASH with fibrosis.
- NASH-induced mice treated with the galectin-inhibitors showed "improved NASH activity and reduced fibrosis including prevention of accumulation of collagen and/or reduced accumulated collagen in the liver."
- Data from a first-in-man Phase 1 study of GR-MD-02 is expected early next year. (PR)
Galectin Therapeutics announces preclinical galectin inhibitor data
Dec 19 2013, 10:34 ET